Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
CME ACTIVITY - Research

Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis

Russell R. KempkerComments to Author , Maia Kipiani, Veriko Mirtskhulava, Nestani Tukvadze, Matthew J. Magee, and Henry M. Blumberg
Author affiliations: Emory University School of Medicine, Atlanta, Georgia, USA (R.R. Kempker, H.M. Blumberg); National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (M. Kipiani, N. Tukvadze); Davit Tvildiani Medical University, Tbilisi (V. Mirtskhulava); Georgia State University School of Public Health, Atlanta (M.J. Magee)

Main Article

Figure 1

Cohort diagram of patients with multidrug-resistant tuberculosis (MDR TB) depicting rates of acquired drug resistance, Georgia, March 2009–October 2012. XDR TB, extensively drug-resistant tuberculosis; OFL, ofloxacin; S, susceptible; CAP, capreomycin; KAN, kanamycin; R, resistant.

Figure 1. Cohort diagram of patients with multidrug-resistant tuberculosis (MDR TB) depicting rates of acquired drug resistance, Georgia, March 2009–October 2012. XDR TB, extensively drug-resistant tuberculosis; OFL, ofloxacin; S, susceptible; CAP, capreomycin; KAN, kanamycin; R, resistant.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external